After an oversubscribed £2.75 mln fundraise Thalia Therapeutics (LON:THAT) buys Sanmirna with its exclusive license in the U.S. for miRisten, a novel treatment for Acute Myeloid Leukaemia.
Chief executive Dr David Solomon says the acquisition is “accretive right away” and is funded “fully to a very important value inflection point.”
In this interview investors will learn:
- Who participated in the recent fundraise validating the company’s belief in the future success of Thalia
- What miRisten is and how it treats leukaemia at this stage of its development
- When top line data from the in-human clinical trial will be published
- What Thalia’s current portfolio contains and whether pharma partnerships are being considered to assist advancement
- How there are very few RNA therapeutics champions in Europe, and this area of biotech is a new burgeoning space globally
- What Solomon, the former CEO of Nasdaq-listed Silence Therapeutics (NASDAQ:SLN), wants to achieve at Thalia
Dr David Solomon, chief executive of Thalia Therapeutics was interviewed by Sarah Lowther for focusIR.
